LT2004079A - Sythetic peptides and uses therof for the prevention and therapy of cancer invasion and metastasis - Google Patents

Sythetic peptides and uses therof for the prevention and therapy of cancer invasion and metastasis

Info

Publication number
LT2004079A
LT2004079A LT2004079A LT2004079A LT2004079A LT 2004079 A LT2004079 A LT 2004079A LT 2004079 A LT2004079 A LT 2004079A LT 2004079 A LT2004079 A LT 2004079A LT 2004079 A LT2004079 A LT 2004079A
Authority
LT
Lithuania
Prior art keywords
peptides
metastasis
sythetic
therapy
prevention
Prior art date
Application number
LT2004079A
Other languages
Lithuanian (lt)
Other versions
LT5328B (en
Inventor
Matthias Rath
Shrirang Netke
Aleksandra Niedzwiecki
Original Assignee
Matthias Rath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matthias Rath filed Critical Matthias Rath
Priority to LT2004079A priority Critical patent/LT5328B/en
Publication of LT2004079A publication Critical patent/LT2004079A/en
Publication of LT5328B publication Critical patent/LT5328B/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to synthetic peptides of the invention comprises PRKPKWDK (SEQ ID:2) peptide corresponding to amino acids of 85 to 92 of the matrix metalloproteinase (MMP-2), and fragments, analogs and homologs to SEQ ID:2. The invention also relates to the uses of such peptides as inhibitory of human cancer invasion and metastasis and further to the therapeutic use in preventing and treating cancer and other pathological conditions related to the degradation of extracellular matrix by MMPs.
LT2004079A 2004-08-23 2004-08-23 Sythetic peptides and uses therof for the prevention and therapy of cancer invasion and metastasis LT5328B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
LT2004079A LT5328B (en) 2004-08-23 2004-08-23 Sythetic peptides and uses therof for the prevention and therapy of cancer invasion and metastasis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LT2004079A LT5328B (en) 2004-08-23 2004-08-23 Sythetic peptides and uses therof for the prevention and therapy of cancer invasion and metastasis

Publications (2)

Publication Number Publication Date
LT2004079A true LT2004079A (en) 2005-10-25
LT5328B LT5328B (en) 2006-03-27

Family

ID=35249178

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2004079A LT5328B (en) 2004-08-23 2004-08-23 Sythetic peptides and uses therof for the prevention and therapy of cancer invasion and metastasis

Country Status (1)

Country Link
LT (1) LT5328B (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5280106A (en) 1988-05-20 1994-01-18 Liotta Lance A Matrix metalloproteinase peptides: role in diagnosis and therapy

Also Published As

Publication number Publication date
LT5328B (en) 2006-03-27

Similar Documents

Publication Publication Date Title
ITMI20021527A1 (en) C5 COMPONENT ANTIBODIES OF COMPLEMENT AND THEIR USE
NZ587105A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
MX2009008270A (en) Novel polypeptide having anti-tumor activity.
TW200744642A (en) Novel peptides for use in the treatment of obesity
MXPA04001033A (en) Anti-cancer and wound healing compounds.
HK1112367A1 (en) Survivin peptide vaccine
RS54215B1 (en) Compositions and methods for diagnosing and treating cancer
HRP20050585A2 (en) Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof
PT2037956E (en) Simultaneous, separate or sequential therapeutic use of at least one botulinum neurotoxin and of at least one opiate derivative
WO2011036443A9 (en) S1 protease c- terminal polypeptides and uses thereof for treating inflammation or coagulation disorders
NZ592911A (en) Leukolectins and uses thereof
NZ596043A (en) Allergy inhibitor compositions and kits and methods of using the same
EP4306123A3 (en) Saposin-a derived peptides and uses thereof
YU76403A (en) Synthetic peptides and uses thereof for the prevention and therapy of cancer invasion and metastasis
LT2004079A (en) Sythetic peptides and uses therof for the prevention and therapy of cancer invasion and metastasis
RU2014134287A (en) BIFUNCTIONAL PEPTID
ATE531384T1 (en) PEPTIDES FROM PLASMINOGEN ACTIVATOR INHIBITOR 1 AND THEIR USE
ATE411812T1 (en) PEPTIDES FOR TREATING HERPES VIRUS INFECTIONS
RS20060023A (en) Use of soluble cd164 in inflammatory and/or autoimmune disorders
ATE544779T1 (en) NOVEL DENDRITIC CELL MIGRATION-INDUCING POLYPEPTIDES, AND MEDICATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
ATE417061T1 (en) SCORPION PEPTIDE AS A BLOOD PRESSURE LOWERING AGENT
GB0228441D0 (en) Splice variant
WO2002053172A3 (en) Use of matrix metalloproteinase peptide substrate to lower the rate of extracellular matrix turnover
WO2004016220A3 (en) Apicomplexan pathways, inhibitiors, and drug delivery
Wall et al. Structural Localization of Light Chain Amyloidogenicity